+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Comparison of diurnal intraocular pressure control by latanoprost versus travoprost : results of an observational survey



Comparison of diurnal intraocular pressure control by latanoprost versus travoprost : results of an observational survey



Clinical Drug Investigation 26(12): 703-714



Intraocular pressure (IOP) is known to be subject to daily fluctuations, the occurrence of which is a risk factor for progression of glaucoma. Control of IOP during the day by drugs is an important therapeutic target. We set out to compare the IOP control of travoprost and latanoprost taking into account the time since last instillation and the time of IOP measurement. This was a prospective, cross-sectional observational study with some retrospective data collection. Private ophthalmologists were selected to each recruit ten patients with primary open-angle glaucoma and/or ocular hypertension receiving either travoprost or latanoprost as monotherapy. Clinical endpoints included IOP measurements and percentage of patients attaining predefined target IOPs. Six patient subgroups were defined according to: (a) IOP measurement time: before 1200h, 1200h-1600h and after 1600h, and (b) time since last intake (<24 hours, >24 hours). Analyses comprised chi(2) and Wilcoxon tests, ANOVA, logistic regressions and adjustment by propensity score. In total, 2052 patients treated with travoprost (n = 1704) or latanoprost (n = 348) participated in the study. Treatment groups were comparable at baseline, except for a longer treatment duration in latanoprost-treated patients. When the interval between the last treatment instillation and IOP measurement (treatment/IOP interval) was <24 hours (n = 1241), 82% of travoprost-treated patients attained pre-defined target IOP versus 67% with latanoprost (p < 0.0001). This difference was greatest after 1600 h, when the mean IOP was 16.5 mm Hg for travoprost-treated patients and 17.7 mm Hg for latanoprost-treated patients (p = 0.0025). When the treatment/IOP interval was >24 hours (n = 461), travoprost was superior to latanoprost, i.e. more patients using travoprost attained the predefined target IOP (78.5% vs 68.3%; p = 0.0344), and the mean IOP value was lower in the travoprost group (16.8 vs 17.8 mm Hg; p = 0.0016). After adjustments for confounding factors, similar results were obtained. According to this observational survey, travoprost appears to reduce evening and mean diurnal IOP more effectively than latanoprost. Latanoprost IOP control appears to be more sensitive to time since the last dose.

(PDF emailed within 1 workday: $29.90)

Accession: 048602725

Download citation: RISBibTeXText

PMID: 17274677


Related references

Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clinical Therapeutics 26(1): 84-91, 2004

Efficacy of latanoprost versus travoprost assessed by daily intraocular pressure curve. Arquivos Brasileiros de Oftalmologia 72(1): 13-17, 2009

Comparison of the effects of latanoprost versus carteolol on the diurnal variation in the intraocular pressure in patients with normal tension glaucoma. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 118, 2003

Comparison of the effects of latanoprost and travoprost on intraocular pressure in chronic angle-closure glaucoma. Journal of Ocular Pharmacology and Therapeutics 22(6): 449-454, 2007

Comparison of the effect of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 4362, 2003

Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 113(2): 239-246, 2006

Latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure results of a 12 week, masked evaluator, multicenter study. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 100, 2003

Intraocular pressure control among patients transitioned from latanoprost to travoprost at a Veterans Affairs Medical Center Eye Clinic. Journal of Ocular Pharmacology and Therapeutics 25(2): 153-157, 2009

Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy. British Journal of Ophthalmology 94(1): 80-84, 2010

A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. American Journal of Ophthalmology 135(5): 688-703, 2003

Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. American Journal of Ophthalmology 137(1): 210-1; Author Reply 211-2, 2004

A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator, multicenter study. American Journal of Ophthalmology 137(2): 387-8; Author Reply 388-9, 2004

Effect of 0.004% travoprost and 0.005% latanoprost on intraocular pressure in dogs. Efeito das solucoes de travoprost 0,004% e de latanoprost 0,005% sobre a pressao intra ocular em caes Canis familiaris LINNAEUS, 1758: 58 pp., 2002

Comparison of dorzolamide/timolol and latanoprost/timolol fixed combinations on diurnal intraocular pressure control in primary open-angle glaucoma. Journal of Ocular Pharmacology and Therapeutics 28(4): 381-386, 2012

Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Advances in Therapy 21(4): 247-262, 2004